Free tool
FAERS Monitor: Zerviate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208694 or its brand name (Zerviate, Cetirizine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
43,309
Serious
34,381
79% of reports
Hospitalization
15,619
Death reported
5,083
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue5,853
- drug ineffective5,324
- pain5,158
- rash5,124
- off label use4,634
- dyspnoea4,628
- pruritus4,543
- arthralgia4,078
- pyrexia3,959
- hypersensitivity3,788
- headache3,709
- nausea3,701
- joint swelling3,614
- swelling3,606
- abdominal discomfort3,550
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 9 |
| 2006 | 34 |
| 2007 | 1 |
| 2008 | 14 |
| 2009 | 149 |
| 2010 | 51 |
| 2011 | 139 |
| 2012 | 575 |
| 2013 | 732 |
| 2014 | 1,189 |
| 2015 | 1,657 |
| 2016 | 2,030 |
| 2017 | 2,063 |
| 2018 | 2,874 |
| 2019 | 3,253 |
| 2020 | 3,691 |
| 2021 | 4,135 |
| 2022 | 3,599 |
| 2023 | 3,845 |
| 2024 | 4,820 |
| 2025 | 5,075 |
| 2026 | 3,370 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,010,850 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| swellingSignal | 3,606 | 19.4 | 18.8 | 60,834 |
| joint swellingSignal | 3,614 | 15.0 | 14.5 | 45,912 |
| abdominal discomfortSignal | 3,550 | 10.5 | 10.1 | 30,022 |
| hypersensitivitySignal | 3,788 | 10.1 | 9.8 | 30,671 |
| pruritusSignal | 4,543 | 5.8 | 5.6 | 18,150 |
| rashSignal | 5,124 | 5.8 | 5.6 | 20,360 |
| pyrexiaSignal | 3,959 | 5.6 | 5.4 | 15,067 |
| arthralgiaSignal | 4,078 | 4.8 | 4.7 | 12,391 |
| painSignal | 5,158 | 4.1 | 4.0 | 12,366 |
| dyspnoeaSignal | 4,628 | 4.0 | 3.9 | 10,588 |
| fatigueSignal | 5,853 | 3.7 | 3.6 | 11,721 |
| headacheSignal | 3,709 | 2.9 | 2.8 | 4,676 |
| off label useSignal | 4,634 | 2.6 | 2.5 | 4,646 |
| nauseaSignal | 3,701 | 2.3 | 2.2 | 2,740 |
| drug ineffective | 5,324 | 2.0 | 1.9 | 2,683 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.